Document is current
Any future updates will be listed below
-
Authors
Cormier-Daire, Valerie
AlSayed, Moeenaldeen
Ben-Omran, Tawfeg
de Sousa, Sérgio Bernardo
Boero, Silvio
Fredwall, Svein O.
Guillen-Navarro, Encarna
Irving, Melita
Lampe, Christian
Maghnie, Mohamad
Mortier, Geert
Peijin, Zagorka
Mohnike, Klaus https://orcid.org/0000-0001-5113-8657
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical
Universitätsklinikum Magdeburg
- License Information
-
More Information
Article History
Received: 16 March 2021
Accepted: 19 July 2021
First Online: 31 July 2021
Declarations
:
: Not applicable.
: Not applicable.
: SB, TB-O, CL and ZP have no conflict of interest to declare. MDS has received honoraria or consultation fees from BioMarin, Sanofi Genzyme and Takeda. SBS has received grants or research support from Therachon/Pfizer and Ascendis and honoraria or consultation fees from BioMarin and Ascendis. VC-D has received honoraria or consultation fees from BioMarin. SF has received consultation fees from BioMarin. EG-N has received grants or research support from BioMarin and Alnylam (paid to her institution) and honoraria or consultation fees from BioMarin, Alnylam, UCB and Takeda. MI has received honoraria or consultation fees from BioMarin, Therachon/Pfizer, Sanofi, QED Therapeutics, Ascendis, Alexion, Kyowa Kirin. MM has received grants or research support from Pfizer and Merck, and honoraria or consultation fees from Pfizer, Merck, Novo Nordisk, Ferring, Ascendis, Sandoz and BioMarin. KM has received honoraria or consultation fees from BioMarin, Kyowa Kirin and QED. GM has received honoraria or consultation fees from BioMarin and Pfizer.
